色素異常症 - 世界市場の考察、競合情勢、市場予測（2030年）

世界の色素異常症の市場規模は、2024年～2030年の予測期間にCAGRで7.31%の成長が推定されます。市場は主に、さまざまな色素異常症の有病率の増加により、大幅な市場成長を示しています。さらに、若年層による皮膚科治療への支出の増加や、美しい外見に対する若年層の意識の高まりなどの要因が、結果として色素異常症市場を支えます。また、ダーマブレージョンやレーザーなどの低侵襲アプローチに対する需要の増加は、今後数年間に市場を押し上げる可能性が高いです。同様に、薬剤や機器の承認の高まりに伴う研究開発活動の増加は、市場における色素異常症の要件を生み出します。したがって、市場は2024年～2030年の予測期間に大幅なCAGRで成長すると推定されます。

色素異常症の市場力学

色素異常症市場の成長に影響を与える主な要因の1つは、世界中でアルビニズム、肝斑、白斑、日光黒子、そばかすなどのさまざまな色素異常症の有病率が増加していることです。

例えば、国連のレポート（2023）によると、北米と欧州では1万7,000人～2万人に1人が何らかのアルビニズムを持っていると推定されています。

前述の資料によれば、アルビニズムの症状はサブサハラアフリカでより一般的であり、タンザニアでは1,400人に1人が罹患していると推定され、ジンバブエや南部アフリカのその他の特定の民族集団では1,000人に1人という高い有病率が報告されています。

Global Vitiligo Foundationによる最新の調査によると、2022年に世界中で7,000万人近くが白斑に罹患しています。

色素異常症は、根本的な疾患に対処するためにさまざまな外用薬、ケミカルピーリング、凍結療法、光/レーザー治療、またはこれらの技術の組み合わせによって治療されます。したがって、世界中でのさまざまな色素異常症の有病率の増加は、外用薬や美容施術の需要を増加させ、2022年～2028年の予測期間に色素異常症の全体的な市場成長を促進します。

最後に、製品の承認や発売の増加などの、市場における戦略的発展の増加は、色素異常症治療市場の成長をさらに高めています。例えば、2022年7月、Incyte Corporationは成人と12歳以上の小児の患者における非分節型白斑の治療薬として、Opzelura（ルキソリチニブ）クリームの承認を米国食品医薬品局から取得しました。

したがって、上記の要因が総体的に、2024年～2030年の予測期間を通じて色素異常症市場全体を牽引します。

しかし、美容施術の高いコストや熟練した専門家の不足などが、予測期間の色素異常症市場の成長を止める可能性があります。

色素異常症市場は、COVID-19パンデミック期間に中程度の影響を受けました。COVID-19の発生当初は、ウイルスの蔓延を抑えるために厳しいロックダウンが課されたため、市場では医療機器や医薬品が大幅に不足しました。さらに、色素異常症患者の治療はCOVID-19患者に比べて優先順位が低かったため、病院や皮膚科クリニックでの治療回数が少なかったです。さらに、サプライチェーンと原材料の混乱により、特定の治療製品の生産が停止しました。しかし、eコマースプラットフォーム上での特定の色素沈着クリームや美容液などの色素異常症治療製品の入手性とともに、市場も緩やかな伸びを示しました。このように、上記の要因が色素異常症市場を軌道に乗せた原因であり、予測期間にも同様のことが見込まれます。

色素異常症市場のセグメント分析

色素異常症市場の治療セグメントでは、2023年にコルチコステロイドセグメントが大きな収益シェアを占めると予測されています。これは、このセグメントに関連するさまざまな利点と用途によるものです。さらに、色素異常症向けコルチコステロイドに関連する主要企業によるさまざまな戦略的方策が、予測期間にコルチコステロイド市場の促進要因となります。

当レポートでは、世界の色素異常症市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 色素異常症市場レポートのイントロダクション

第2章 色素異常症市場のエグゼクティブサマリー

• 調査範囲
• 市場の概要
• 競合の評価

第3章 規制分析

第4章 色素異常症市場の主な要因の分析

• 色素異常症市場の促進要因
• 色素異常症市場の抑制要因と課題
• 色素異常症市場の機会

第5章 色素異常症市場のポーターのファイブフォース分析

第6章 色素異常症市場に対するCOVID-19の影響の分析

第7章 色素異常症の市場レイアウト

• 治療法別
  • 薬物療法
  • 非薬物療法/美容治療
• 適応症別
  • アルビニズム
  • 白斑
  • 肝斑
  • 炎症後色素沈着（PIH）
  • その他
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 色素異常症市場の企業と製品のプロファイル

• AbbVie Inc.
• DERMAMED SOLUTIONS
• obagi Cosmeceuticals LLC.
• Incyte Corporation.
• Pierre Fabre group
• GALDERMA LABORATORIES, L.P.
• Alvogen.
• SkinCeuticals.
• Arcutis Biotherapeutics, Inc.
• Bausch Health Companies Inc.
• Dr. Reddy's Laboratories Ltd
• Dermavant Sciences, Inc.
• Glenmark Pharmaceuticals
• Zerigo Health.
• Novartis AG
• Pfizer Inc.
• Merz GmbH & Co. KGaA
• Viatris Inc.
• Uniza Healthcare
• PCA SKIN

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項、お問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Pigmentation Disorder Market
• Table 3: Pigmentation Disorder Market Analysis in Global (2021-2030)
• Table 4: Pigmentation Disorder Market Analysis in Global by Treatment (2021-2030)
• Table 5: Pigmentation Disorder Market Analysis in Global by Indication (2021-2030)
• Table 6: Pigmentation Disorder Market Analysis in Global by Geography (2021-2030)
• Table 7: Pigmentation Disorder Market Analysis in North America (2021-2030)
• Table 8: Pigmentation Disorder Market Analysis in North America by Country (2021-2030)
• Table 9: Pigmentation Disorder Market Analysis in the US (2021-2030)
• Table 10: Pigmentation Disorder Market Analysis in Canada (2021-2030)
• Table 11: Pigmentation Disorder Market Analysis in Mexico (2021-2030)
• Table 12: Pigmentation Disorder Market Analysis in Europe (2021-2030)
• Table 13: Pigmentation Disorder Market Analysis in Europe by Country (2021-2030)
• Table 14: Pigmentation Disorder Market Analysis in France (2021-2030)
• Table 15: Pigmentation Disorder Market Analysis in Germany (2021-2030)
• Table 16: Pigmentation Disorder Market Analysis in the UK (2021-2030)
• Table 17: Pigmentation Disorder Market Analysis in Italy (2021-2030)
• Table 18: Pigmentation Disorder Market Analysis in Spain (2021-2030)
• Table 19: Pigmentation Disorder Market Analysis in the Rest of Europe (2021-2030)
• Table 20: Pigmentation Disorder Market Analysis in Asia-Pacific (2021-2030)
• Table 21: Pigmentation Disorder Market Analysis in Asia-Pacific by Country (2021-2030)
• Table 22: Pigmentation Disorder Market Analysis in China (2021-2030)
• Table 23: Pigmentation Disorder Market Analysis in Japan (2021-2030)
• Table 24: Pigmentation Disorder Market Analysis in India (2021-2030)
• Table 25: Pigmentation Disorder Market Analysis in Australia (2021-2030)
• Table 26: Pigmentation Disorder Market Analysis in South Korea (2021-2030)
• Table 27: Pigmentation Disorder Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Table 28: Pigmentation Disorder Market Analysis in the Rest of the World (2021-2030)
• Table 29: Pigmentation Disorder Market Analysis in the Rest of the World by Region (2021-2030)
• Table 30: Pigmentation Disorder Market Analysis in the Middle East (2021-2030)
• Table 31: Pigmentation Disorder Market Analysis in Africa (2021-2030)
• Table 32: Pigmentation Disorder Market Analysis in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Pigmentation Disorder Market
• Figure 3: Pigmentation Disorder Market Analysis in Global (2021-2030)
• Figure 4: Pigmentation Disorder Market Analysis in Global by Treatment (2021-2030)
• Figure 5: Pigmentation Disorder Market Analysis in Global by Indication (2021-2030)
• Figure 6: Pigmentation Disorder Market Analysis in Global by Geography (2021-2030)
• Figure 7: Pigmentation Disorder Market Analysis in North America (2021-2030)
• Figure 8: Pigmentation Disorder Market Analysis in North America by Country (2021-2030)
• Figure 9: Pigmentation Disorder Market Analysis in the US (2021-2030)
• Figure 10: Pigmentation Disorder Market Analysis in Canada (2021-2030)
• Figure 11: Pigmentation Disorder Market Analysis in Mexico (2021-2030)
• Figure 12: Pigmentation Disorder Market Analysis in Europe (2021-2030)
• Figure 13: Pigmentation Disorder Market Analysis in Europe by Country (2021-2030)
• Figure 14: Pigmentation Disorder Market Analysis in France (2021-2030)
• Figure 15: Pigmentation Disorder Market Analysis in Germany (2021-2030)
• Figure 16: Pigmentation Disorder Market Analysis in the UK (2021-2030)
• Figure 17: Pigmentation Disorder Market Analysis in Italy (2021-2030)
• Figure 18: Pigmentation Disorder Market Analysis in Spain (2021-2030)
• Figure 19: Pigmentation Disorder Market Analysis in the Rest of Europe (2021-2030)
• Figure 20: Pigmentation Disorder Market Analysis in Asia-Pacific (2021-2030)
• Figure 21: Pigmentation Disorder Market Analysis in Asia-Pacific by Country (2021-2030)
• Figure 22: Pigmentation Disorder Market Analysis in China (2021-2030)
• Figure 23: Pigmentation Disorder Market Analysis in Japan (2021-2030)
• Figure 24: Pigmentation Disorder Market Analysis in India (2021-2030)
• Figure 25: Pigmentation Disorder Market Analysis in Australia (2021-2030)
• Figure 26: Pigmentation Disorder Market Analysis in South Korea (2021-2030)
• Figure 27: Pigmentation Disorder Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Figure 28: Pigmentation Disorder Market Analysis in the Rest of the World (2021-2030)
• Figure 29: Pigmentation Disorder Market Analysis in the Rest of the World by Region (2021-2030)
• Figure 30: Pigmentation Disorder Market Analysis in the Middle East (2021-2030)
• Figure 31: Pigmentation Disorder Market Analysis in Africa (2021-2030)
• Figure 32: Pigmentation Disorder Market Analysis in South America (2021-2030)
• Figure 33: Market Drivers
• Figure 34: Market Barriers
• Figure 35: Market Opportunities
• Figure 36: PORTER's Five Force Analysis

Pigmentation Disorder Market By Treatment (Pharmacological Treatment [Corticosteroids, Calcineurin Inhibitors, And Others] And Non-Pharmacological/Cosmetic Treatment [Chemical Peels, Laser Treatment, Phototherapy, And Others]), By Indication (Albinism, Vitiligo, Melasma, Post-Inflammatory Hyperpigmentation (PIH), And Others), and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing prevalence of pigmentation disorder such as albinism, melasma, vitiligo, freckles, and others and increasing demand of minimally invasive approaches for pigmentation treatment such as dermabrasion, laser, and others, across the globe

The global pigmentation disorder market is estimated to grow at a CAGR of 7.31% during the forecast period from 2024 to 2030. The pigmentation disorder market is witnessing considerable market growth primarily owing to the increasing prevalence of various pigmentation disorders. Further, the growing expenditure by young adults on dermatological treatments along with the surging awareness among youngsters about aesthetic appearance, and other factors will ultimately support the market of pigmentation disorders. Also, increasing demand for minimally invasive approaches such as dermabrasion, and laser among others will likely contribute towards pushing the market of pigmentation disorder in the forthcoming years. Similarly, the increasing research & developmental activities along with the rising drug and device approvals will create a requisite for pigmentation disorder in the market. Therefore, the market for pigmentation disorder is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

Pigmentation Disorder Market Dynamics:

One of the key factors influencing the growth of the pigmentation disorders market is the increasing prevalence of various pigmentation disorders such as albinism, melasma, vitiligo, solar lentigines, ephelides (freckles), and others, across the globe.

For instance, as per the United Nations report (2023), it was estimated that in North America and Europe 1 in every 17,000 to 20,000 people have some form of albinism.

As per the above-mentioned source, the condition of albinism is much more prevalent in sub-Saharan Africa, with estimates of 1 in 1,400 people being affected in Tanzania and prevalence as high as 1 in 1,000 reported for select populations in Zimbabwe and other specific ethnic groups in Southern Africa.

According to the latest study done by Global Vitiligo Foundation, nearly 70 million people across the world had vitiligo, in 2022.

The pigmentation diseases are treated with various topical medicines, chemical peels, cryotherapy, light or laser therapy, or a combination of these techniques to address the underlying illness. Thus, the increasing prevalence of various pigmentation disorders globally will increase the demand for topical medicines or cosmetic procedures, thereby propelling the overall market growth of pigmentation disorders during the forecast period from 2022 - 2028.

Lastly, the increasing strategic development in the market such as rising product approvals, and launches are further increasing the growth of the pigmentation disorder treatment market. For instance, in July 2022, Incyte Corporation received approval from the United States Food and Drug Administration for Opzelura (ruxolitinib) cream for the treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.

Therefore, the factors stated above collectively will drive the overall pigmentation disorder market throughout the forecast period from 2024-2030.

However, the high cost of cosmetic procedures, lack of skilled professionals, and others may halt the market growth of pigmentation disorders during the forecast period.

The pigmentation disorder market was moderately impacted during the period of COVID- 19 pandemic. At the onset of the disease, there was a significant shortage of devices and drugs in the market, attributed to the imposition of stringent lockdowns to curb the spread of the virus. Moreover, treatment for patients suffering from pigmentation disorders was not a priority in comparison to the patients that were suffering from coronavirus, resulting in a lesser number of treatment sessions in the hospital or dermatological clinics. Additionally, owing to the disruption in the supply chain and raw materials, the production of certain treatment products was shut down. However, with the availability of certain pigmentation creams, serums, and other pigmentation treating products over the e-commerce platforms, the market witnessed a moderate rise also. Thus, the above factor was responsible for bringing the market of pigmentation disorder back on track and is anticipated to do the same during the forecast period.

Pigmentation Disorder Market Segment Analysis:

Pigmentation Disorder Market by Treatment (Pharmacological Treatment [Corticosteroids, Calcineurin Inhibitors, and Others] and Non-Pharmacological/Cosmetic Treatment [Chemical Peels, Laser Treatment, Phototherapy, and Others]), Indication (Albinism, Vitiligo, Melasma, Post-Inflammatory Hyperpigmentation (PIH), and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the treatment segment of the pigmentation disorder market, the corticosteroids segment is expected to have a significant revenue share in the year 2023. This is owing to the various advantages and applications that are associated with the segment. Further, various strategic steps taken by the key players pertaining to corticosteroids for pigmentation disorders will aid in driving the market of corticosteroids during the forecast period.

The topical corticosteroids (TC) application showed quick amelioration of post-inflammatory hyperpigmentation patches. Moreover, corticosteroid drugs are used for the treatment of various pigmentation diseases such as albinism, melasma, vitiligo, solar lentigines, ephelides (freckles), and others.

Also, corticosteroids may be used with non-pharmacological treatment for fasting the process of pigmentation treatment.

Further, various developmental activities by key players such as acquisitions, launches, partnerships, and others will also increase the demand for corticosteroids in the market. For instance, in July 2022, Ahammune Biosciences collaborated with Veeda Clinical Research Limited for investigating AB1001 as a topical therapy for vitiligo.

Therefore, owing to the above-mentioned factors, the demand for corticosteroids will increase during the forecast period, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the global pigmentation disorder market.

North America is expected to dominate the overall Pigmentation Disorder Market:

Among all the regions, North America is expected to dominate the global pigmentation disorder in the year 2023 and is expected to do the same during the forecast period from 2024-2030.

This domination is due to the increasing prevalence of pigmentation disorders, the rising geriatric population prone to pigmentation disorders, and technological advancements in treatment options that will boost the pigmentation disorders Market in North America.

For instance, as per the report, people with albinism worldwide, 2022 in the United States, the prevalence of oculocutaneous albinism type 2 was 1 in 6,500 people, in 2022. The increasing prevalence of albinism will increase the demand for topical drugs and cosmetic procedures employed in the treatment of pigmentation disorder.

Further, the availability of various products by the top market competitors, including Obagi Cosmeceuticals, Alvogen, and AbbVie Inc., and increasing business strategies such as mergers, acquisitions, and product launches to strengthen their market position are all anticipated to fuel the market expansion.

For instance, in February 2020, Eli Lilly acquired Dermira for USD 1.1 billion. This acquisition assists the company to expand its pipeline of dermatology medicines, and others with the addition of lebrikizumab, for the treatment of moderate-to-severe atopic dermatitis in adolescent and adult patients, ages 12 years and older and QBREXZA, for the topical treatment of primary axillary hyperhidrosis, respectively.

Therefore, the interplay of the aforementioned factors would provide a conducive growth environment for the pigmentation disorder market in North America.

Pigmentation Disorder Market Key Players:

Some of the key market players operating in the pigmentation disorder market include AbbVie Inc., DERMAMED SOLUTIONS, obagi Cosmeceuticals LLC., Incyte Corporation., Pierre Fabre group, GALDERMA LABORATORIES, L.P., Alvogen., SkinCeuticals., Arcutis Biotherapeutics, Inc., Bausch Health Companies Inc., Dr. Reddy's Laboratories Ltd, Dermavant Sciences, Inc., Glenmark Pharmaceuticals, Zerigo Health., Novartis AG, Pfizer Inc., Merz GmbH & Co. KGaA, Viatris Inc., Uniza Healthcare, PCA SKIN, and others.

Recent Developmental Activities in the Pigmentation Disorder Market:

In February 2022, Scientis, an emerging leader in the science of skin discoloration, announces the launch of Cyspera® Intensive System(TM), a new three-product system clinically proven to improve hyperpigmentation such as persistent brown patches and dark spots.

In February 2020, PCA SKIN launches two of its most popular chemical peels. These new launches have been added to its extensive lineup of custom blended peel options. The new trichloroacetic (TCA) peel formulas include PCA SKIN Sensi Peel, for people with sensitive skin, PCA SKIN Ultra Peel which can be used for many other skin types, conditions, and sensitivities, and PCA SKIN MD Peel (CCl3) which is most suitable for resilient skin.

Key Takeaways from the Pigmentation Disorder Market Report Study

• Market size analysis for current pigmentation disorder market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the pigmentation disorder market.
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global pigmentation disorder market.
• Various opportunities available for the other competitor in the pigmentation disorder market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030.
• Which are the top-performing regions and countries in the current pigmentation disorder market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for pigmentation disorder market growth in the coming future?

Target Audience who can be benefited from this Pigmentation Disorder Market Report Study

• Pigmentation disorder providers
• Research organizations and consulting companies
• Pigmentation disorder-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in pigmentation disorder
• Various end users who want to know more about the pigmentation disorder market and the latest developments in the pigmentation disorder market.

Frequently Asked Questions for the Pigmentation Disorder Market:

1. What is pigmentation disorder?

The pigmentation disorders include a large number of diverse conditions that are usually characterized by altered melanocyte density, melanin concentration, or both and result in altered pigmentation of the skin. Pigmentation disorders are classified as hypopigmentation and hyperpigmentation. In hypopigmentation, the pigment is decreased, whereas, in depigmentation, the pigment is completely lost, leaving white skin.

2. What is the global market for pigmentation disorder?

The global pigmentation disorder market is estimated to grow at a CAGR of 7.31% during the forecast period from 2024 to 2030.

3. What are the drivers for the global pigmentation disorder market?

The pigmentation disorder market is witnessing positive market growth owing to the factors such as the increasing prevalence of pigmentation disorders, growing expenditure on dermatological treatments, surging awareness among youngsters about aesthetic appearance, increasing demand for minimally invasive approaches such as dermabrasion, laser, and other, surging new drug launches and approvals, presence of key players in the market, and others will create an exigency for the pigmentation disorder market.

4. Who are the key players operating in the global pigmentation disorder market?

Some of the key market players operating in the pigmentation disorder market include AbbVie Inc., DERMAMED SOLUTIONS, obagi Cosmeceuticals LLC., Incyte Corporation., Pierre Fabre group, GALDERMA LABORATORIES, L.P., Alvogen., SkinCeuticals., Arcutis Biotherapeutics, Inc., Bausch Health Companies Inc., Dr. Reddy's Laboratories Ltd, Dermavant Sciences, Inc., Glenmark Pharmaceuticals, Zerigo Health., Novartis AG, Pfizer Inc., Merz GmbH & Co. KGaA, Viatris Inc., Uniza Healthcare, PCA SKIN, and others.

5. Which region has the highest share of the pigmentation disorder market?

Among all the regions, North America is estimated to hold a significant revenue share in the global pigmentation disorder market. This can be ascribed to the due the increasing prevalence of pigmentation disorders, the rising geriatric population prone to pigmentation disorders, advancements in devices and drugs, the rising awareness about skincare, and the presence of key domicile players in the region are the reasons which act as a supportive factor for the North America pigmentation disorder market growth.

Table of Contents

1.Pigmentation Disorder Market Report Introduction

2. Pigmentation Disorder Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

4. Pigmentation Disorder Market Key Factors Analysis

• 4.1. Pigmentation Disorder Market Drivers
  • 4.1.1. Increasing prevalence of pigmentation disorders
  • 4.1.2. Growing expenditure on dermatological treatments
  • 4.1.3. Surging awareness among youngsters about the aesthetic appearance
  • 4.1.4. Increasing demand for minimally invasive approaches such as dermabrasion, laser, and others
• 4.2. Pigmentation Disorder Market Restraints and Challenges
  • 4.2.1. High cost of cosmetic procedures
  • 4.2.2. Lack of skilled professionals
• 4.3. Pigmentation Disorder Market Opportunities
  • 4.3.1. Increasing strategic initiatives such as product launches or collaboration by the key players

5. Pigmentation Disorder Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Pigmentation Disorder Market

7. Pigmentation Disorder Market Layout

• 7.1. By Treatment
  • 7.1.1. Pharmacological Treatment
    • 7.1.1.1. Corticosteroids
    • 7.1.1.2. Calcineurin Inhibitors
    • 7.1.1.3. Others
  • 7.1.2. Non-Pharmacological/Cosmetic Treatment
    • 7.1.2.1. Chemical Peels
    • 7.1.2.2. Laser Treatment
    • 7.1.2.3. Phototherapy
    • 7.1.2.4. Others
• 7.2. By Indication
  • 7.2.1. Albinism
  • 7.2.2. Vitiligo
  • 7.2.3. Melasma
  • 7.2.4. Post-inflammatory Hyperpigmentation (PIH)
  • 7.2.5. Others
• 7.3. By Geography
  • 7.3.1. North America
    • 7.3.1.1. United States Pigmentation Disorder Market in USD million (2021-2030)
    • 7.3.1.2. Canada Pigmentation Disorder Market in USD million (2021-2030)
    • 7.3.1.3. Mexico Pigmentation Disorder Market in USD million (2021-2030)
  • 7.3.2. Europe
    • 7.3.2.1. France Pigmentation Disorder Market in USD million (2021-2030)
    • 7.3.2.2. Germany Pigmentation Disorder Market in USD million (2021-2030)
    • 7.3.2.3. United Kingdom Pigmentation Disorder Market in USD million (2021-2030)
    • 7.3.2.4. Italy Pigmentation Disorder Market in USD million (2021-2030)
    • 7.3.2.5. Spain Pigmentation Disorder Market in USD million (2021-2030)
    • 7.3.2.6. Rest of Europe Pigmentation Disorder Market in USD million (2021-2030)
  • 7.3.3. Asia-Pacific
    • 7.3.3.1. China Pigmentation Disorder Market in USD million (2021-2030)
    • 7.3.3.2. Japan Pigmentation Disorder Market in USD million (2021-2030)
    • 7.3.3.3. India Pigmentation Disorder Market in USD million (2021-2030)
    • 7.3.3.4. Australia Pigmentation Disorder Market in USD million (2021-2030)
    • 7.3.3.5. South Korea Pigmentation Disorder Market in USD million (2021-2030)
    • 7.3.3.6. Rest of Asia Pacific Pigmentation Disorder Market in USD million (2021-2030)
  • 7.3.4. Rest of the World (RoW)
    • 7.3.4.1. Middle East Pigmentation Disorder Market in USD million (2021-2030)
    • 7.3.4.2. Africa Pigmentation Disorder Market in USD million (2021-2030)
    • 7.3.4.3. South America Pigmentation Disorder Market in USD million (2021-2030)

8. Pigmentation Disorder Market Company and Product Profiles

• 8.1. AbbVie Inc.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. DERMAMED SOLUTIONS
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. obagi Cosmeceuticals LLC.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Incyte Corporation.
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Pierre Fabre group
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. GALDERMA LABORATORIES, L.P.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Alvogen.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. SkinCeuticals.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Arcutis Biotherapeutics, Inc.
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Bausch Health Companies Inc.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Dr. Reddy's Laboratories Ltd
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Dermavant Sciences, Inc.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Glenmark Pharmaceuticals
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Zerigo Health.
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Novartis AG
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Pfizer Inc.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Merz GmbH & Co. KGaA
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Viatris Inc.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Uniza Healthcare
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. PCA SKIN
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us